Sweta Modha works as a Packaging Technician at Apotex. AAM is recognizing dedicated people like Sweta who show up each day for America's patients. She is proud to work to ensure the supply chain continuity of essential medicines during the #COVID19 public health emergency.
AAM Board Chair Alok Sonig at Lupin: "We are working night and day globally across our manufacturing footprint to make sure our essential employees are able to come to our sites... and despite the challenges are able to make the product that is critically needed globally and we are doing that." #covid19
AAM Survey of Biosimilars and Generic Drug Manufacturers Reveals Average of 224% Increase In Cost of Transporting Drugs
WASHINGTON, DC (April 30, 2020) — The Association for Accessible Medicines today released “A Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain,” a six-element framework that lays out concrete actions that the federal government could take to ensure that U.S. patients and the U.S. health care system have access to a secure and consistent supply of critical pharmaceuticals.
Anthony Maffia works in New Jersey at Sandoz as Vice President, Head of Regulatory Affairs, North America.
AAM is recognizing dedicated people like Anthony and his peers across the generic & biosimilar industry who show up each day for US patients.
The industry is "finding new and creative and rapid ways to get medication into the hands of patients that need it.”
Roby Epting is a manager of second-shift operations at Sandoz in Wilson, North Carolina.
AAM is recognizing dedicated people like Roby and his peers across the generics and biosimilars industry who show up each day for U.S. patients.
"We are just excited to be able to contribute in any kind of way."
Learn more at: https://accessiblemeds.org/COVID-19-FAQs
This presentation includes:
On Friday, March 27, 2020, AAM and 68 signatories signed on to a letter to President Trump expressing our opposition to proposed “Buy American” requirements that would make it harder for the U.S. government to purchase medicines produced using ingredients from outside the U.S — especially in the middle of a public health emergency.
Administration’s Plan Embraces Getting More Generic and Biosimilar Medicines to Patients
WASHINGTON DC (May 11, 2018) – In President Trump’s remarks today at the White House, he made clear the essential role that generic and biosimilar medicines play in containing prescription drug costs for patients.
Continued from Part 1...
We greatly appreciate the FDA’s efforts to increase the number of generic drug approvals and take action on applications in the backlog.
What some people also might not understand is that not all generic medicines approved by the FDA make it to market.